SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:prod.swepub.kib.ki.se:1945219"
 

Sökning: onr:"swepub:oai:prod.swepub.kib.ki.se:1945219" > A 1-year, randomize...

  • Winblad, BKarolinska Institutet (författare)

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD

  • Artikel/kapitelEngelska2001

Förlag, utgivningsår, omfång ...

  • 2001-08-14
  • Ovid Technologies (Wolters Kluwer Health),2001

Nummerbeteckningar

  • LIBRIS-ID:oai:prod.swepub.kib.ki.se:1945219
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:1945219URI
  • https://doi.org/10.1212/wnl.57.3.489DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Objective: To evaluate the long-term clinical efficacy and safety of donepezil versus placebo over 1 year in patients with mild to moderate AD.Methods: Patients (n = 286; mean age, 72.5 years) with possible or probable AD from five Northern European countries were randomized to receive either donepezil (n = 142; 5 mg/day for 28 days, followed by 10 mg/day) or placebo (n = 144) for 1 year.Results: The study was completed by 66.9% of the donepezil- and 67.4% of the placebo-treated patients. The benefit of donepezil over placebo was demonstrated by the Gottfries-Bråne-Steen (a global assessment for rating dementia symptoms) total score at weeks 24, 36, and 52 (p < 0.05) and at the study end point (week 52, last observation carried forward; p = 0.054). Advantages of donepezil over placebo were also observed in cognition and activities of daily living (ADL) assessed by the Mini-Mental State Examination at weeks 24, 36, and 52, and the end point (p < 0.02) and by the Progressive Deterioration Scale at week 52 and the end point (p < 0.05). Adverse events (AE) were recorded for 81.7% of donepezil- and 75.7% of placebo-treated patients, with 7% of donepezil- and 6.3% of placebo-treated patients discontinuing because of AE. Treatment response to donepezil was not predicted by APOE genotype or sex in this population.Conclusion: As the first 1-year, multinational, double-blinded, placebo-controlled study of a cholinesterase inhibitor in AD, these data support donepezil as a well tolerated and effective long-term treatment for patients with AD, with benefits over placebo on global assessment, cognition, and ADL.

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Engedal, K (författare)
  • Soininen, H (författare)
  • Verhey, F (författare)
  • Waldemar, G (författare)
  • Wimo, AKarolinska Institutet (författare)
  • Wetterholm, AL (författare)
  • Zhang, R (författare)
  • Haglund, A (författare)
  • Subbiah, P (författare)
  • Karolinska Institutet (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Neurology: Ovid Technologies (Wolters Kluwer Health)57:3, s. 489-4950028-38781526-632X

Internetlänk

Hitta via bibliotek

  • Neurology (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy